IL302154A - Anticancer compounds for estrogen receptor positive cancer - Google Patents

Anticancer compounds for estrogen receptor positive cancer

Info

Publication number
IL302154A
IL302154A IL302154A IL30215423A IL302154A IL 302154 A IL302154 A IL 302154A IL 302154 A IL302154 A IL 302154A IL 30215423 A IL30215423 A IL 30215423A IL 302154 A IL302154 A IL 302154A
Authority
IL
Israel
Prior art keywords
compound
erso
dfp
trifluoromethyl
nmr
Prior art date
Application number
IL302154A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of IL302154A publication Critical patent/IL302154A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL302154A 2020-10-23 2021-10-21 Anticancer compounds for estrogen receptor positive cancer IL302154A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063104933P 2020-10-23 2020-10-23
PCT/US2021/056003 WO2022087234A1 (en) 2020-10-23 2021-10-21 Anticancer compounds selective for er-positive cancers

Publications (1)

Publication Number Publication Date
IL302154A true IL302154A (en) 2023-06-01

Family

ID=81290080

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302154A IL302154A (en) 2020-10-23 2021-10-21 Anticancer compounds for estrogen receptor positive cancer

Country Status (9)

Country Link
US (1) US12655104B2 (enExample)
EP (1) EP4232038A4 (enExample)
JP (1) JP2023546584A (enExample)
CN (1) CN116723841A (enExample)
AU (2) AU2021366688B2 (enExample)
CA (1) CA3196210A1 (enExample)
IL (1) IL302154A (enExample)
MX (1) MX2023004480A (enExample)
WO (1) WO2022087234A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120981469A (zh) * 2023-02-23 2025-11-18 晨晖生物科技(香港)有限公司 含硼化合物及其治疗用途
WO2026039467A1 (en) * 2024-08-12 2026-02-19 The Board Of Trustees Of The University Of Illinois Hydroxyphenyl-indoline-2-one cancer therapeutics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2855406A (en) 1955-05-07 1958-10-07 Dann Otto Preparation of benzopyrans and benzofurans
US3773759A (en) 1972-08-21 1973-11-20 Searle & Co 1-arylideneamino-4-(2-oxo-3-phenyl-3-benzofuryl)piperazines
FR2810320B1 (fr) 2000-06-19 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
CA2684552A1 (en) * 2007-04-24 2008-10-30 Topotarget A/S Substituted 3-(4-hydroxyphenyl)-indolin-2-one compounds
EA027139B1 (ru) 2013-04-26 2017-06-30 Бейджин, Лтд. Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
CN108440378B (zh) 2018-03-27 2021-03-12 宁波大学 一种室温下碘-双氧水促进的3-氨基-2-吲哚酮衍生物的制备方法
EP3817741A4 (en) * 2018-07-03 2022-07-06 The Board of Trustees of the University of Illinois ACTIVATORS OF THE UNFOLDING PROTEIN RESPONSE

Also Published As

Publication number Publication date
AU2021366688A9 (en) 2024-06-20
MX2023004480A (es) 2023-05-04
US12655104B2 (en) 2026-06-16
EP4232038A4 (en) 2024-04-10
AU2021366688A1 (en) 2023-05-25
JP2023546584A (ja) 2023-11-06
EP4232038A1 (en) 2023-08-30
AU2026204244A1 (en) 2026-06-18
CA3196210A1 (en) 2022-04-28
WO2022087234A1 (en) 2022-04-28
US20230391721A1 (en) 2023-12-07
CN116723841A (zh) 2023-09-08
AU2021366688B2 (en) 2026-03-05

Similar Documents

Publication Publication Date Title
US10525056B2 (en) Procaspase-activating compounds and methods
US20220119429A1 (en) Fluorine-containing compound and anti-cancer medical use thereof
JP2022513959A5 (enExample)
CA2879798C (en) Procaspase enzyme-activating substituted 2-(4-benzylpiperazin-1-yl)-n'-(2-hydroxybenzylidene)acetohydrazide derivatives and compostions thereof
JP2024512544A (ja) テトラヒドロナフタレン系化合物、その製造方法及びその医薬的応用
TW202135831A (zh) 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
US20210340100A1 (en) Activators of the unfolded protein response
US20260103470A1 (en) Androgen receptor regulation by small molecule enantiomers
AU2021366688B2 (en) Anticancer compounds selective for er-positive cancers
US20220089602A1 (en) Compounds that induce ferroptic cell death
WO2021222738A1 (en) Compounds for estrogen receptor positive cancers
US11274106B2 (en) Topoisomerase inhibitors with antibacterial and anticancer activity
US20250376477A1 (en) Analgesic delta opioid receptor bitopic ligands
US12552806B2 (en) Androgen receptor regulation by small molecule enantiomers
WO2026039467A1 (en) Hydroxyphenyl-indoline-2-one cancer therapeutics
US11731947B2 (en) Deuterated antimicrobial compounds
WO2025029660A9 (en) Compounds with selectivity for certain cancers
KR20100047495A (ko) 신규 갈바닉산 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물
JPH04356447A (ja) トリフェニルアルケン誘導体及びそれを含有する腫瘍抑制作用を有する医薬組成物